Alternative Data for Trevi Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 17 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,803 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Trevi Therapeutics
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
| Price | $11.20 |
| Target Price | Sign up |
| Volume | 1,863,021 |
| Market Cap | $1.51B |
| Year Range | $5.86 - $14.17 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026March 10 - GlobeNewswire |
|
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic CoughMarch 9 - GlobeNewswire |
|
Trevi Therapeutics to Participate in Upcoming March ConferencesMarch 2 - GlobeNewswire |
|
 |
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 16 - Yahoo |
 |
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough ControlMarch 10 - SeekingAlpha |
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in MarchMarch 9 - Yahoo |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -12M | -12M | -0.080 |
| Q2 '25 | 0 | 38,000 | -38,000 | -12M | -12M | -0.090 |
| Q1 '25 | 0 | 37,000 | -37,000 | -10M | -10M | -0.090 |
| Q4 '24 | 150,000 | 38,000 | -38,000 | -11M | -11M | -0.110 |
| Q3 '24 | 0 | 36,000 | -36,000 | -13M | -13M | -0.130 |
Insider Transactions View All
| SCIASCIA THOMAS filed to sell 221,373 shares at $6.6. March 26 '25 |
| GOOD JENNIFER L filed to sell 213,313 shares at $6.6. March 25 '25 |
| Simon Farrell filed to sell 76,900 shares at $7.1. March 12 '25 |
| Simon Farrell filed to sell 81,250 shares at $6.7. March 12 '25 |
| GOOD JENNIFER L filed to sell 213,313 shares at $3. September 9 '24 |
Similar companies
Read more about Trevi Therapeutics (TRVI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Trevi Therapeutics
The Market Cap of Trevi Therapeutics is $1.51B.
Currently, the price of one share of Trevi Therapeutics stock is $11.20.
The TRVI stock price chart above provides a comprehensive visual representation of Trevi Therapeutics 's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Trevi Therapeutics shares. Our platform offers an up-to-date TRVI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Trevi Therapeutics (TRVI) does not offer dividends to its shareholders. Investors interested in Trevi Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Trevi Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
